For research use only. Not for therapeutic Use.
CFT8634 is an oral activity degrader targeting BRD9 extracted from patent WO2021178920A1 compound 174. CFT8634 can be used for the research of synovial sarcoma and SMARCB1-deleted solid tumors[1][2].
| Catalog Number | I043847 |
| CAS Number | 2704617-96-7 |
| Synonyms | (3R)-3-[4-[4-[(4S)-1-[[2,6-dimethoxy-4-(1,4,5-trimethyl-6-oxopyridin-3-yl)phenyl]methyl]-3,3-difluoropiperidin-4-yl]piperazin-1-yl]-3-fluoroanilino]piperidine-2,6-dione |
| Molecular Formula | C37H45F3N6O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C37H45F3N6O5/c1-22-23(2)36(49)43(3)19-26(22)24-16-31(50-4)27(32(17-24)51-5)20-44-11-10-33(37(39,40)21-44)46-14-12-45(13-15-46)30-8-6-25(18-28(30)38)41-29-7-9-34(47)42-35(29)48/h6,8,16-19,29,33,41H,7,9-15,20-21H2,1-5H3,(H,42,47,48)/t29-,33+/m1/s1 |
| InChIKey | GNRGNRCQXHMQQV-CPBHLAHYSA-N |
| SMILES | CC1=C(C(=O)N(C=C1C2=CC(=C(C(=C2)OC)CN3CCC(C(C3)(F)F)N4CCN(CC4)C5=C(C=C(C=C5)NC6CCC(=O)NC6=O)F)OC)C)C |
| Reference | [1]. Nasveschuk CG, et, al. Compounds for targeted degradation of brd9. WO2021178920A1. [2]. Brian A, et.al. A Phase 1/2 Study of CFT8634, a Novel Bifunctional Degradation Activating Compound (BIDACmDegrader Of BRD9, in Synovial Sarcoma and SMARCB1-null Tumors. |
